Groundbreaking
COVID-19 Pathogen Adsorption Therapy
ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter is a groundbreaking hemoperfusion technology that addresses unmet clinical needs for treating severe COVID-19.
An Exciting Option for Critical Care Teams
The Seraph 100 uses microbead adsorption media with chemically-bonded modified heparin to mimic the binding sites that COVID-19 uses when they invade the bloodstream. COVID-19 is removed from the bloodstream, and once bound, remains in the filter.
In the News
See what’s happening at ExThera Medical and recent updates about the Seraph 100 and ONCObind.
ExThera Medical Receives MTEC Award for Pivotal Sepsis Trial
ExThera Announces Completion of Phase I OSCAR I Trial
Revolutionary Trial Aims to Transform Pancreatic Cancer Treatment
Breakthrough technology study for patients suffering from life-threatening bloodstream infections proceeds into next phase with first patient enrollment
MM-00017 Rev F